Why the study?
To evaluate QTc changes associated with tyrosine kinase inhibitors and identify factors related to these changes in cancer patients.
What is the prevalence of and risk factors for QTc prolongation in cancer patients taking tyrosine kinase inhibitors?
What is the prevalence of and risk factors for QTc prolongation in cancer patients taking tyrosine kinase inhibitors?
Answers are grounded in this paper and cite their sources.
A significant proportion (34.5%) of cancer patients on tyrosine kinase inhibitors for over three months develop QTc prolongation, particularly those with advanced age and longer duration of use.
Objective: To look for QTc changes associated with tyrosine kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: This correlational study was conducted in Avicenna Medical College and Hospital Lahore with the collaboration of SKMH during November 2020 to May 2021. Methodology: One hundred and eighty patients with solid or hematological malignancies taking tyrosine kinase inhibitors for more than three months were included in the study. They underwent 12 lead ECG inside oncology department. QTc interval was calculated on ECG of all the patients and they were evaluated for presence of prolonged QT interval. Age, gender, duration of tyrosine kinase inhibitor use and presence of comorbid illness were correlated with presence of QTc changes in our study participants. Results: Out of 180 cancer patients using tyrosine kinase inhibitors for more than three months included in the study, 96 (53.3%) were male while 84 (46.7%) were female. One hundred and eighteen (65.5%) had normal QTc interval while 62 (34.5%) had prolonged QTc interval in our study participants. Binary logistic regression analysis revealed that advanced age of the patient and prolong use of tyrosine kinase inhibitors was statistically significantly associated with QTc prolongation in our study (p-value<0.001). Conclusion: Significant number of cancer patients using tyrosine kinase inhibitors had prolonged QTc interval in our study. Special attention should be paid to the cancer patients with advancing age and prolonged use of tyrosine kinase inhibitors.
No takes yet. Share an insight, caveat, or question.
Zaka et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: